Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer... | NCT05116189 | Trialant

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer... | NCT05116189 | Trialant

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No
Eligibility Criteria: Inclusion Criteria:

Has histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Has received 1 or 2 prior lines of systemic therapy for ovarian cancer (OC), including at least 1 prior platinum-based therapy. Participants may have received a prior poly (ADP-ribose) polymerase inhibitor (PARPi), anti-programmed cell death 1 protein (PD-1)/anti-programmed cell death ligand 1 (PD-L1) therapy, bevacizumab, or hormonal therapy; these will not be considered a separate line of therapy. Any chemotherapy regimen change due to toxicity in the absence of disease progression will be considered part of the same line of therapy.

Has provided documented informed consent for the study.

Has radiographic evidence of disease progression within 6 months (180 days) after the last dose of platinum-based chemotherapy for OC (i.e., platinum-resistant disease).

Is a candidate for paclitaxel chemotherapy (and bevacizumab, if using).

Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 3 days before randomization.

For a female participant, she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP) OR Is a WOCBP and uses a contraceptive method that is highly effective (with a failure rate of <1% per year).

Has radiographically evaluable disease, either measurable or nonmeasurable per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, as assessed by the local site investigator.

Archival tumor tissue sample or newly obtained core or incisional/excisional biopsy of a tumor lesion not previously irradiated has been provided.

Have adequate organ function.

Exclusion Criteria:

Has nonepithelial cancers, borderline tumors, mucinous, seromucinous that is predominantly mucinous, malignant Brenner's tumor and undifferentiated carcinoma.

Has primary platinum-refractory disease, defined as disease that has progressed per radiographic imaging while receiving or within 28 days of the last dose of first-line platinum-based therapy.

Has prior disease progression on weekly paclitaxel alone.

Has received >2 prior lines of systemic therapy for OC.

Has received prior systemic anticancer therapy including investigational agents or maintenance therapy (including bevacizumab maintenance therapy), within 4 weeks before randomization.

Has received prior radiation therapy within 2 weeks of start of study intervention.

Has not recovered adequately from surgery and/or any complications from the surgery.

Has received colony-stimulating factors (e.g., granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor,[GM-CSF] or recombinant erythropoietin) within 4 weeks before randomization.

Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.

Has received investigational agent or has used an investigational device within 4 weeks prior to study intervention.

Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.

Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.

Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

Has severe hypersensitivity (≥Grade 3) to pembrolizumab, paclitaxel, or bevacizumab (if using) and/or any of their excipients.

Has an active autoimmune disease that has required systemic treatment in the past 2 years.

Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.

Has an active infection requiring systemic therapy.

Has a known history of human immunodeficiency virus (HIV) infection.

Has a known history of Hepatitis B or known active Hepatitis C virus infection.

Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study.

Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.

Participant, in the judgement of the investigator, is unlikely to comply with the study procedures, restrictions, and requirements of the study.

Has had an allogenic tissue/solid organ transplant.

For bevacizumab treatment

Has uncontrolled hypertension.

Has current, clinically relevant bowel obstruction including related to underlying epithelial OC, abdominal fistula or gastrointestinal perforation, intra-abdominal abscess, or evidence of rectosigmoid involvement by pelvic exam.

Has a history of thrombotic disorders, hemorrhage, hemoptysis, or active gastrointestinal bleeding within 6 months before randomization.

HonorHealth ( Site 0041)

Phoenix, Arizona 85016, United States

Marin Cancer Care ( Site 0055)

Greenbrae, California 94904, United States

Pacific Cancer Care ( Site 0028)

Monterey, California 93940, United States

Eisenhower Medical Center ( Site 0067)

Rancho Mirage, California 92270, United States

Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0004)

New Haven, Connecticut 06511, United States

University of Florida College of Medicine-UF Health Cancer Center/Clinical Trials Office ( Site 0054

Gainesville, Florida 32610, United States

Sarasota Memorial Hospital ( Site 0018)

Sarasota, Florida 34239, United States

Moffitt Cancer Center ( Site 0033)

Tampa, Florida 33612, United States

Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0005)

Marietta, Georgia 30060, United States

Advocate Medical Group-Oncology ( Site 0049)

Park Ridge, Illinois 60068, United States

Parkview Research Center at Parkview Regional Medical Center ( Site 0027)

Fort Wayne, Indiana 46845, United States

St. Vincent Hospital and Health Care Center, Inc ( Site 0032)

Indianapolis, Indiana 46260, United States

Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0040)

Edgewood, Kentucky 41017, United States

WK Physicians Network / Hematology Oncology Associates ( Site 0034)

Shreveport, Louisiana 71103, United States

Mercy Medical Center - Baltimore-Medical Oncology and Hematology ( Site 0015)

Baltimore, Maryland 21202, United States

University of Massachusetts Chan Medical School-Division of Gynecologic Oncology ( Site 0003)

Worcester, Massachusetts 01605, United States

John Theurer Cancer Center at Hackensack University Medical Center ( Site 0007)

Hackensack, New Jersey 07601, United States

Roswell Park Cancer Institute ( Site 0039)

Buffalo, New York 14263, United States

Columbia University Medical Center ( Site 0010)

New York, New York 10032, United States

Novant Health Presbyterian Medical Center ( Site 0029)

Charlotte, North Carolina 28204, United States

Duke Cancer Institute ( Site 0038)

Durham, North Carolina 27710, United States

Novant Health Forsyth Medical Center ( Site 0057)

Winston-Salem, North Carolina 27103, United States

Aultman Hospital-Oncology Clinical Trials ( Site 0009)

Canton, Ohio 44710, United States

MetroHealth Medical Center-Cancer Care Center ( Site 0047)

Cleveland, Ohio 44109, United States

Providence Portland Medical Center ( Site 0048)

Portland, Oregon 97213, United States

University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0024)

Pittsburgh, Pennsylvania 15219, United States

Sanford Cancer Center ( Site 0064)

Sioux Falls, South Dakota 57104, United States

The West Clinic, PLLC dba West Cancer Center ( Site 0058)

Germantown, Tennessee 38138, United States

Texas Oncology - Dallas (Presbyterian) ( Site 0065)

Dallas, Texas 75231, United States

Texas Oncology - The Woodlands_Lee ( Site 0043)

The Woodlands, Texas 77380, United States

Inova Schar Cancer Institute ( Site 0019)

Fairfax, Virginia 22031, United States

Westmead Hospital-Department of Gynaecological Oncology ( Site 0201)

Westmead, New South Wales 2145, Australia

Gallipoli Medical Research Foundation-GMRF CTU ( Site 0202)

Brisbane, Queensland 4120, Australia

Epworth Freemasons ( Site 0204)

Melbourne, Victoria 3002, Australia

St. John of God Subiaco Hospital ( Site 0203)

Subiaco, Western Australia 6008, Australia

Institut Jules Bordet-Medicine Oncology ( Site 0302)

Brussels, Bruxelles-Capitale, Region de 1000, Belgium

UZ Gent-Medical oncology ( Site 0301)

Ghent, Oost-Vlaanderen 9000, Belgium

UZ Leuven ( Site 0303)

Leuven, Vlaams-Brabant 3000, Belgium

AZ Groeninge Campus Kennedylaan-Oncology ( Site 0305)

Kortrijk, West-Vlaanderen 8500, Belgium

Hospital Araújo Jorge ( Site 0401)

Goiânia, Goiás 74605-070, Brazil

Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0404)

Natal, Rio Grande do Norte 59075-740, Brazil

ANIMI - Unidade de Tratamento Oncologico ( Site 0408)

Lages, Santa Catarina 88501001, Brazil

BP - A Beneficencia Portuguesa de São Paulo ( Site 0403)

São Paulo, São Paulo 01323-001, Brazil

Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0405)

São Paulo, São Paulo 04014-002, Brazil

Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA-Pesquisa Clinica HC II ( Site 0402)

Rio de Janeiro, 20220-410, Brazil

Tom Baker Cancer Center ( Site 0511)

Calgary, Alberta T2N 4N2, Canada

BC Cancer Abbotsford ( Site 0512)

Abbotsford British Columbia, British Columbia V2S 0C2, Canada

BC Cancer Victoria ( Site 0513)

Victoria, British Columbia V8R 6V5, Canada

Kingston Health Sciences Centre-Kingston General Hospital Si-Oncology and/or Hematology - Gynecolog

Kingston, Ontario K7L 2V7, Canada

Sunnybrook Health Sciences - Odette Cancer Centre ( Site 0508)

Toronto, Ontario M4N 3M5, Canada

CIUSSS de l'Est-de-l'Île-de-Montréal ( Site 0501)

Montreal, Quebec H1T 2M4, Canada

Jewish General Hospital ( Site 0505)

Montreal, Quebec H3T 1E2, Canada

McGill University Health Centre ( Site 0502)

Montreal, Quebec H4A 3J1, Canada

Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0

Québec, Quebec G1J 1Z4, Canada

Saskatoon Cancer Center ( Site 0510)

Saskatoon, Saskatchewan S7N 4H4, Canada

James Lind Centro de Investigación del Cáncer ( Site 0602)

Temuco, Araucania 4780000, Chile

CIDO SpA-Oncology ( Site 0608)

Temuco, Araucania 4810148, Chile

Clínica Puerto Montt ( Site 0601)

Port Montt, Los Lagos Region 5500243, Chile

Oncovida ( Site 0603)

Santiago, Region M. de Santiago 7510032, Chile

Instituto de Radiomedicina-hemato-oncologia ( Site 0604)

Santiago, Region M. de Santiago 7630370, Chile

Clínica Vespucio-Hemato - Ocology ( Site 0607)

Santiago, Region M. de Santiago 8241479, Chile

Pontificia Universidad Catolica de Chile-Centro del Cáncer ( Site 0609)

Santiago, Region M. de Santiago 8330032, Chile

Bradfordhill ( Site 0605)

Santiago, Region M. de Santiago 8420383, Chile

Anhui Provincial Hospital-Obstetrics and Gynecology ( Site 0709)

Hefei, Anhui 230001, China

Beijing Cancer hospital ( Site 0711)

Beijing, Beijing Municipality 100142, China

Beijing Peking Union Medical College Hospital-Gynecological center of tumor ( Site 0702)

Beijing, Beijing Municipality 100730, China

Fujian Provincial Cancer Hospital ( Site 0713)

Fuzhou, Fujian 350014, China

Lanzhou university second hospital ( Site 0734)

Lanzhou, Gansu 730030, China

Zhujiang Hospital ( Site 0739)

Guangzhou, Guangdong 510280, China

Affiliated Hospital of Guangdong Medical University ( Site 0743)

Zhanjiang, Guangdong 524004, China

Guangxi Medical University Affiliated Tumor Hospital ( Site 0717)

Nanning, Guangxi 530021, China

Hainan General Hospital ( Site 0736)

Haikou, Hainan 570311, China

Henan Cancer Hospital ( Site 0718)

Zhengzhou, Henan 450008, China

Wuhan Union Hospital-Medical Oncology ( Site 0735)

Wuhan, Hubei 430022, China

Hubei Cancer Hospital-Hubei Cancer Hospital ( Site 0708)

Wuhan, Hubei 430079, China

Xiangya Hospital Central South University-Gynecology ( Site 0705)

Changsha, Hunan 410008, China

Hunan Cancer Hospital ( Site 0704)

Changsha, Hunan 410013, China

Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Oncology (

Nanjing, Jiangsu 210000, China

Zhongda Hospital Southeast University ( Site 0723)

Nanjing, Jiangsu, China

Jiangxi Maternal and Child Health Hospital-Oncology Department ( Site 0716)

Nanchang, Jiangxi 330006, China

The First Hospital of Jilin University ( Site 0710)

Changchun, Jilin 130021, China

Shandong Cancer Hospital-Oncology Department ( Site 0733)

Jinan, Shandong 250117, China

LinYi Cancer Hospital ( Site 0731)

Linyi, Shandong 276001, China

Obstetrics & Gynecology Hospital of Fudan University ( Site 0715)

Shanghai, Shanghai Municipality 200011, China

Fudan University Shanghai Cancer Center-Gynecologic Oncology Department ( Site 0701)

Shanghai, Shanghai Municipality 200032, China

Shanghai First Maternity and Infant Hospital-Gynecology department ( Site 0744)

Shanghai, Shanghai Municipality 201204, China

West China Second University Hospital Sichuan University ( Site 0740)

Chengdu, Sichuan 610066, China

Tianjin Central Hosptial of Gynecology Obstetrics ( Site 0737)

Tianjin, Tianjin Municipality 300052, China

Tianjin Medical University Cancer Institute and Hospital ( Site 0720)

Tianjin, Tianjin Municipality 300060, China

Yunnan Province Cancer Hospital-Gynecology Department ( Site 0714)

Kunming, Yunnan 650106, China

The Affiliated Women's Hospital of Zhejiang University-Obstetrics and Gynecology ( Site 0741)

Hangzhou, Zhejiang 3100000, China

The First Affiliated Hospital of Wenzhou Medical University-Gynecology ( Site 0706)

Wenzhou, Zhejiang 325000, China

Fundación Colombiana de Cancerología Clínica Vida ( Site 0808)

Medellín, Antioquia 050030, Colombia

Clinica de la Costa LTDA-Clinical Research Oncology & Hematology -Pediatric ( Site 0809)

Barranquilla, Atlántico 080020, Colombia

Clínica Universitaria Colombia ( Site 0806)

Bogotá, Bogota D.C. 111221, Colombia

Oncologos del Occidente ( Site 0807)

Pereira, Risaralda Department 660001, Colombia

Hemato Oncologos SA ( Site 0801)

Cali, Valle del Cauca Department 76001, Colombia

Aalborg Universitetshospital, Syd ( Site 0901)

Aalborg, North Denmark 9000, Denmark

Turku University Hospital-Department of Obstetrics and Gynecology ( Site 1001)

Turku, Southwest Finland 20521, Finland

Centre Hospitalier Régional Universitaire de Brest - Hôpital-Institut de cancérologie et hématologi

Brest, Brittany Region 29200, France

Centre François Baclesse-Recherche clinique ( Site 2904)

Caen, Calvados 14076, France

Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren-oncologie ( Site 2907)

Limoges, Haute-Vienne 87042, France

Institut Curie - site Saint-Cloud ( Site 2909)

Saint-Cloud, Hauts-de-Seine 92210, France

Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer-Medical Oncology ( Site 2901)

Rennes, Ille-et-Vilaine 35042, France

Centre de Cancérologie du Grand Montpellier ( Site 2908)

Montpellier, Languedoc-Roussillon 34070, France

Hôpital privé du Confluent SAS-Service d'oncologie médicale ( Site 2905)

Nantes, Loire-Atlantique 44277, France

Universitaetsklinikum Erlangen-Klinik für Gynäkologie und Geburtshilfe ( Site 1205)

Erlangen, Bavaria 91054, Germany

Universitätsklinikum Bonn-Gynaecological oncology ( Site 1203)

Bonn, North Rhine-Westphalia 53127, Germany

Universitaetsklinikum Duesseldorf-Klinik für Frauenheilkunde & Geburtshilfe ( Site 1204)

Düsseldorf, North Rhine-Westphalia 40225, Germany

Zentrum fuer ambulante gynaekologische Onkologie (ZAGO) ( Site 1207)

Krefeld, North Rhine-Westphalia 47805, Germany

CaritasKlinikum Saarbrücken St. Theresia ( Site 1211)

Saarbrücken, Saarland 66113, Germany

Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Frauenheilkunde und Gebur

Dresden, Saxony 01307, Germany

Universitätsklinikum Leipzig-Department of Gynecology and Obstetrics ( Site 1213)

Leipzig, Saxony 04103, Germany

Charité Campus Virchow-Klinikum ( Site 1201)

Berlin, 13353, Germany

Asklepios Kliniken Hamburg-Asklepios Klinik Barmbek ( Site 1214)

Hamburg, 22307, Germany

St. James's Hospital-Cancer clinical trials office ( Site 2821)

Dublin, D08 E9P6, Ireland

Emek Medical Center-Gyn-Onc ( Site 1406)

Afula, 1834111, Israel

Soroka Medical Center ( Site 1404)

Beersheba, 8410101, Israel

Rambam Health Care Campus-Gyneco-oncology unit ( Site 1402)

Haifa, 3109601, Israel

Shaare Zedek Medical Center ( Site 1405)

Jerusalem, 9103102, Israel

Rabin Medical Center ( Site 1401)

Petah Tikva, 49100, Israel

Sheba Medical Center ( Site 1407)

Ramat Gan, 5265601, Israel

Sourasky Medical Center ( Site 1403)

Tel Aviv, 6423906, Israel

IRCCS - AOU di Bologna-SSD Oncologia medica Addarii ( Site 1501)

Bologna, Emilia-Romagna 40138, Italy

Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1503)

Milan, Lombardy 20133, Italy

Ospedale San Gerardo-ASST Monza-Oncologia ( Site 1508)

Monza, Lombardy 20900, Italy

ASST Grande Ospedale Metropolitano Niguarda ( Site 1505)

Milan, Milano 20162, Italy

Ospedale Mauriziano-Ginecologia e Ostetricia ( Site 1507)

Turin, Piedmont 10128, Italy

Azienda Ospedaliera Spedali Civili di Brescia ( Site 1504)

Brescia, 25123, Italy

Istituto Europeo di Oncologia IRCCS-Divisione di Ginecologia Oncologica ( Site 1502)

Milan, 20141, Italy

Aichi Cancer Center Hospital ( Site 1610)

Nagoya, Aichi-ken 464-8681, Japan

National Cancer Center Hospital East ( Site 1609)

Kashiwa, Chiba 277-8577, Japan

National Hospital Organization Shikoku Cancer Center ( Site 1603)

Matsuyama, Ehime 791-0280, Japan

Ehime University Hospital ( Site 1606)

Tōon, Ehime 791-0295, Japan

Kurume University Hospital ( Site 1607)

Kurume, Fukuoka 830-0011, Japan

Hokkaido University Hospital ( Site 1604)

Sapporo, Hokkaido 060-8648, Japan

Iwate Medical University Hospital ( Site 1613)

Shiwa-gun Yahaba-cho, Iwate 028-3695, Japan

Nippon Medical School Musashi Kosugi Hospital ( Site 1614)

Kawasaki, Kanagawa 211-8533, Japan

Saitama Medical University International Medical Center ( Site 1601)

Hidaka-shi, Saitama 350-1200, Japan

Shizuoka Cancer Center ( Site 1611)

Nakatogari, Shizuoka 411-8777, Japan

National Cancer Center Hospital ( Site 1612)

Chuo-ku, Tokyo 104-0045, Japan

Japanese Foundation for Cancer Research ( Site 1605)

Koto, Tokyo 135-8550, Japan

Osaka International Cancer Institute ( Site 1602)

Osaka, 541-8567, Japan

Investigación Oncofarmacéutica-Investigación clínica ( Site 1706)

La Paz, Baja California Sur 23040, Mexico

COI Centro Oncologico Internacional S.A.P.I. de C.V.-Investigation Unit COI ( Site 1703)

Mexico City, Mexico City 04700, Mexico

INSTITUTO NACIONAL DE CANCEROLOGIA ( Site 1701)

Mexico City, Mexico City 14070, Mexico

iCan Oncology Center Centro Medico AVE ( Site 1704)

Monterrey, Nuevo León 64710, Mexico

Centro de Investigacion Clinica de Oaxaca ( Site 1705)

Oaxaca City, 68020, Mexico

Radboudumc ( Site 1802)

Nijmegen, Gelderland 6525 GA, Netherlands

Leids Universitair Medisch Centrum-Medical Oncology ( Site 1801)

Leiden, South Holland 2333 ZA, Netherlands

Erasmus Medisch Centrum-Medical Oncology ( Site 1803)

Rotterdam, South Holland 3015 GD, Netherlands

Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 1804)

Utrecht, 3584 CX, Netherlands

Auckland City Hospital ( Site 1901)

Auckland, 1023, New Zealand

Universitetssykehuset Nord-Norge HF-Kreftavdelingen ( Site 2001)

Tromsø, Troms 9038, Norway

Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Me-Oddzial Ginekologii Onkologicznej ( Sit

Poznan, Greater Poland Voivodeship 61-848, Poland

Szpital Kliniczny im. Księżnej Anny Mazowieckiej ( Site 2103)

Warsaw, Masovian Voivodeship 00-315, Poland

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Gynecological Oncology Department ( Sit

Warsaw, Masovian Voivodeship 02-781, Poland

Bialostockie Centrum Onkologii-Oddzial Onkologii Ginekologicznej ( Site 2106)

Bialystok, Podlaskie Voivodeship 15-027, Poland

Uniwersytecki Szpital Kliniczny w Bialymstoku-Uniwersyteckie Centrum Onkologii ( Site 2104)

Bialystok, Podlaskie Voivodeship 15-276, Poland

Uniwersyteckie Centrum Kliniczne-Klinika Ginekologii, Ginekologii Onkologicznej i Endokrynologii Gi

Gdansk, Pomeranian Voivodeship 80-214, Poland

Narodowy Instytut Onkologii - Oddzial w Gliwicach-III Klinika Radioterapii i Chemioterapii ( Site 21

Gliwice, Silesian Voivodeship 44-101, Poland

Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 2107)

Kielce, Świętokrzyskie Voivodeship 25-734, Poland

Chelyabinsk Regional Clinical Oncology Dispensary-Chelyabinsk Regional Clinical Oncology Dispensary

Chelyabinsk, Chelyabinsk Oblast 454087, Russia

Ogarev Mordovia State University ( Site 2209)

Saransk, Mordoviya, Respublika 430005, Russia

Fed State Budgetary Inst "N.N. Blokhin Med Center of Oncology" MHRF-Chemotherapy #2 ( Site 2211)

Moscow, Moscow 115478, Russia

Moscow City Oncology Hospital #62 ( Site 2214)

Krasnogorsk D-t, Moscow Oblast 143423, Russia

SVERDLOVSK REGIONAL ONCOLOGY DISPENSARY-Oncogynecology Department ( Site 2216)

Yekaterinburg, Sverdlovsk Oblast 620905, Russia

Seoul National University Hospital ( Site 2302)

Seoul, 03080, South Korea

Severance Hospital, Yonsei University Health System-Gynecologic cancer center ( Site 2303)

Seoul, 03722, South Korea

Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology ( Site 2304)

Seoul, 05505, South Korea

Gangnam Severance Hospital ( Site 2301)

Seoul, 06273, South Korea

cukurova universty ( Site 2706)

Sarçam, Adana 01250, Turkey (Türkiye)

Istanbul Universitesi Cerrahpasa ( Site 2709)

Fatih, Istanbul 34098, Turkey (Türkiye)

Ege University Medicine of Faculty ( Site 2702)

Bornova, İzmir 35100, Turkey (Türkiye)

Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 2704)

Adana, 01250, Turkey (Türkiye)

Ankara University Hospital Cebeci ( Site 2701)

Ankara, 06100, Turkey (Türkiye)

Baskent Universitesi Ankara Hastanesi ( Site 2707)

Ankara, 34180, Turkey (Türkiye)

Bezmialem Vakf Üniversitesi-Oncology ( Site 2705)

Istanbul, 34093, Turkey (Türkiye)

T.C. Saglik Bakanligi Turkiye Kamu Hastaneleri Kurumu - Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma

Istanbul, 34440, Turkey (Türkiye)

Brighton and Sussex University Hospitals NHS Trust ( Site 2803)

East Sussex, Brighton And Hove BN2 5BE, United Kingdom

Addenbrooke's Hospital ( Site 2808)

Cambridge, Cambridgeshire CB2 2QQ, United Kingdom

The Royal Cornwall Hospital ( Site 2804)

Truro, Cornwall TR1 3LJ, United Kingdom

Westmorland General Hospital ( Site 2815)

Kendal, Cumbria LA9 7RG, United Kingdom

Ninewells Hospital and Medical School ( Site 2826)

Dundee, Dundee City DD1 9SY, United Kingdom

Leicester Royal Infirmary-HOPE Clinical Trials Unit ( Site 2812)

Leicester, England, United Kingdom

Hammersmith Hospital-Medical Oncology ( Site 2818)

London, London, City of W12 0HS, United Kingdom

Velindre Cancer Centre ( Site 2805)

Cardiff, CF14 2TL, United Kingdom